Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.45 |
| ▸ | F3 | P13726 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13686073 | 1.00 | CYP1A2 (0.45) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL17988234 | 1.00 | CYP1A2 (0.45) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL13686075 | 0.88 | CYP1A2 (0.39) | CYP1A2F3MAPTSMN1; SMN2HSD11B1 | |
| SCHEMBL10021977 | 0.88 | CYP1A2 (0.39) | CYP1A2F3MAPTSMN1; SMN2HSD11B1 | |
| SCHEMBL13513062 | 0.87 | ALDH1A1 (0.38) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL17975264 | 0.84 | CYP1A2 (0.36) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL17975258 | 0.84 | CYP1A2 (0.36) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL17975263 | 0.84 | CYP1A2 (0.36) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL17975259 | 0.84 | CYP1A2 (0.36) | CYP1A2F3EGFRNFE2L2MAPT | |
| SCHEMBL18574579 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270689-A1 | TREATMENT OF ALZHEIMER'S DISEASE | KNEPPER PAUL A (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230270689-A1 | TREATMENT OF ALZHEIMER'S DISEASE | KNEPPER PAUL A (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4212151-A2 | STILBENE, FLAVONOL OR CURCUMIN COMPOUNDS FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD; ARMD) | Knepper, Paul A. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2020167951-A1 | COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | KNEPPER PAUL A (US) | 2020-08-20 | — | — | WO | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20140360366-A1 | AZIDE CROSSLINKED AND PHYSICALLY CROSSLINKED POLYMERS FOR MEMBRANE SEPARATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2014047174-A1 | RADIATION CURED MEMBRANES DERIVED FROM POLYMERS THAT ARE CO-REACTIVE WITH AZIDE CROSSLINKING AGENT(S) | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2013043807-A1 | AZIDE CROSSLINKED AND PHYSICALLY CROSSLINKED POLYMERS FOR MEMBRANE SEPARATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-03-28 | — | — | WO | disclosed |
| US-8119041-B2 | A polymerizable monomer or polymerizable oligomer and at least a two-photon absorption material containing aliphatic ketone compounds with atleast 2-8 double bonds and two aromatic or heteroaromatic rings | FUJIFILM CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110065126-A1 | SUBSTANCE-IMMOBILIZING SUBSTRATE, SUBSTANCE-IMMOBILIZED SUBTRATE, AND ANALYSIS METHOD | RIKEN (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065126-A1 | SUBSTANCE-IMMOBILIZING SUBSTRATE, SUBSTANCE-IMMOBILIZED SUBTRATE, AND ANALYSIS METHOD | RIKEN (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP1A2 2166/4885F3 4264/4885EGFR 3201/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | CYP1A2 1507/4885F3 4252/4885EGFR 3882/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | CYP1A2 2544/4885F3 4781/4885EGFR 4187/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | CYP1A2 1507/4885F3 4252/4885EGFR 3882/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP1A2 2166/4885F3 4264/4885EGFR 3201/4885 |
| US-20230270689-A1 | TREATMENT OF ALZHEIMER'S DISEASE | TLR4, TLR2, PSEN2 | CYP1A2 2074/4885F3 4094/4885EGFR 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.